DMP.DE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	20 896.00
Średni wolumen	21 880.00
Kapitalizacja rynkowa	1.81B
EPS	€0 ( 2024-03-27 )
Następna data zysków	( €0 ) 2024-05-15
Last Dividend	€1.050 ( 2023-06-15 )
Next Dividend	€0 ( N/A )
P/E	27.85
ATR14	€0.0820 (0.24%)

Wolumen Korelacja

Długi: 0.08 (neutral)

Krótki: -0.35 (neutral)

Signal:(55.805) Neutral

Dermapharm Holding SE Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dermapharm Holding SE Korelacja - Waluta/Towar

0.29
( neutral )

0.03
( neutral )

-0.37
( neutral )

-0.26
( neutral )

-0.34
( neutral )

Dermapharm Holding SE Finanse

Annual	2023
Przychody:	€1.14B
Zysk brutto:	€342.86M (30.20 %)
EPS:	€1.160

FY	2023
Przychody:	€1.14B
Zysk brutto:	€342.86M (30.20 %)
EPS:	€1.160

FY	2022
Przychody:	€1.02B
Zysk brutto:	€660.83M (64.49 %)
EPS:	€2.49

FY	2021
Przychody:	€942.91M
Zysk brutto:	€620.69M (65.83 %)
EPS:	€3.89

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€1.050 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.49 - Stable (29.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.770	2019-06-05
Last Dividend	€1.050	2023-06-15
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	€5.67	--
Avg. Dividend % Per Year	0.00%	--
Score	3.15	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.49
Div. Directional Score	8.66	--

Next Divdend (Est)
(2025-03-31)

€0.606 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.15

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
RNT.F	Ex Dividend Junior	2023-09-13	Annually	0.00%
BIRG.DE	Ex Dividend Junior	2023-05-11	Sporadic	0.00%
ITU.DE	Ex Dividend Knight	2023-10-06	Quarterly	0.00%
TNE5.DE	Ex Dividend Junior	2023-12-12	Semi-Annually	0.00%
CSH.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
MBB.DE	Ex Dividend Junior	2023-06-13	Annually	0.00%
WIB.DE	Ex Dividend Knight	2023-05-09	Annually	0.00%
ENI.DE	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%
OPC.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0549	1.500	8.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0286	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.114	1.500	9.84	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.598	0.800	7.01	5.61	[1 - 3]
quickRatioTTM	0.760	0.800	-0.238	-0.191	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.489	-1.500	1.855	-2.78	[0 - 0.6]
interestCoverageTTM	3.07	1.000	9.98	9.98	[3 - 30]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.24	2.00	8.38	10.00	[0 - 20]
debtEquityRatioTTM	1.979	-1.500	2.08	-3.13	[0 - 2.5]
grossProfitMarginTTM	0.543	1.000	4.28	4.28	[0.2 - 0.8]
operatingProfitMarginTTM	0.156	1.000	8.88	8.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.203	1.000	9.99	9.99	[0.2 - 2]
assetTurnoverTTM	0.520	0.800	9.87	7.89	[0.5 - 2]
Total Score				10.83

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	28.92	1.000	7.18	0	[1 - 100]
returnOnEquityTTM	0.114	2.50	9.90	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.24	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	3.13	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.01	2.00	8.66	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	22.27	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.190	1.000	7.74	0	[0.1 - 0.5]
Total Score				6.49

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.